Does the media favor BNTX or REGN?

In the previous week, Regeneron Pharmaceuticals had 21 more articles in the media than BioNTech. MarketBeat recorded 41 mentions for Regeneron Pharmaceuticals and 20 mentions for BioNTech. BioNTech's average media sentiment score of 0.44 beat Regeneron Pharmaceuticals' score of 0.42 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 9 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Regeneron Pharmaceuticals 7 Very Positive mention(s) 6 Positive mention(s) 18 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral

Which has better valuation & earnings, BNTX or MRNA?

BioNTech has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNTech $3.25B 7.42 -$1.29B -$7.83 N/A Moderna $1.94B 40.35 -$2.82B -$7.99 N/A

Is BNTX or MRNA more profitable?

BioNTech has a net margin of -63.54% compared to Moderna's net margin of -141.43%. BioNTech's return on equity of -6.86% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -63.54% -6.86% -6.00% Moderna -141.43% -28.30% -19.39%

Does the media prefer BNTX or MRNA?

In the previous week, Moderna had 26 more articles in the media than BioNTech. MarketBeat recorded 46 mentions for Moderna and 20 mentions for BioNTech. BioNTech's average media sentiment score of 0.44 beat Moderna's score of 0.13 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 9 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 10 Very Positive mention(s) 10 Positive mention(s) 16 Neutral mention(s) 7 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has better valuation & earnings, BNTX or ARGX?

argenex has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNTech $3.25B 7.42 -$1.29B -$7.83 N/A argenex $4.25B 13.67 $1.29B $26.04 35.65

Is BNTX or ARGX more profitable?

argenex has a net margin of 32.19% compared to BioNTech's net margin of -63.54%. argenex's return on equity of 43.59% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -63.54% -6.86% -6.00% argenex 32.19% 43.59% 36.66%

Does the media prefer BNTX or ARGX?

In the previous week, BioNTech had 16 more articles in the media than argenex. MarketBeat recorded 20 mentions for BioNTech and 4 mentions for argenex. BioNTech's average media sentiment score of 0.44 beat argenex's score of 0.43 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 9 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral argenex 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, NTRA or BNTX?

Natera has higher earnings, but lower revenue than BioNTech. Natera is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 24.72 -$208.16M -$1.36 N/A BioNTech $3.25B 7.42 -$1.29B -$7.83 N/A

Is NTRA or BNTX more profitable?

Natera has a net margin of -7.11% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Natera -7.11% -11.38% -7.87% BioNTech -63.54% -6.86% -6.00%

Does the media refer more to NTRA or BNTX?

In the previous week, BioNTech had 2 more articles in the media than Natera. MarketBeat recorded 20 mentions for BioNTech and 18 mentions for Natera. BioNTech's average media sentiment score of 0.44 beat Natera's score of 0.26 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral BioNTech 9 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RVMD or BNTX?

In the previous week, BioNTech had 11 more articles in the media than Revolution Medicines. MarketBeat recorded 20 mentions for BioNTech and 9 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.59 beat BioNTech's score of 0.44 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 9 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

BioNTech (BNTX) Competitors

$92.35 -2.90 (-3.04%)

As of 02:25 PM Eastern

Compare

BNTX vs. REGN, MRNA, ARGX, NTRA, and RVMD

Should you buy BioNTech stock or one of its competitors? BioNTech's main competitors and comparable companies include Regeneron Pharmaceuticals (REGN), Moderna (MRNA), argenex (ARGX), Natera (NTRA), and Revolution Medicines (RVMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioNTech compare to Regeneron Pharmaceuticals?

BioNTech (NASDAQ:BNTX) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BioNTech presently has a consensus price target of $125.69, indicating a potential upside of 31.96%. Regeneron Pharmaceuticals has a consensus price target of $814.88, indicating a potential upside of 9.80%. Given BioNTech's higher possible upside, analysts clearly believe BioNTech is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.69

Regeneron Pharmaceuticals has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.42	-$1.29B	-$7.83	N/A
Regeneron Pharmaceuticals	$14.34B	5.33	$4.50B	$40.46	18.34

Regeneron Pharmaceuticals has a net margin of 27.86% compared to BioNTech's net margin of -63.54%. Regeneron Pharmaceuticals' return on equity of 13.47% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

In the previous week, Regeneron Pharmaceuticals had 21 more articles in the media than BioNTech. MarketBeat recorded 41 mentions for Regeneron Pharmaceuticals and 20 mentions for BioNTech. BioNTech's average media sentiment score of 0.44 beat Regeneron Pharmaceuticals' score of 0.42 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	9 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Regeneron Pharmaceuticals	7 Very Positive mention(s)	6 Positive mention(s)	18 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral

BioNTech has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.16, meaning that its share price is 84% less volatile than the broader market.

Summary

Regeneron Pharmaceuticals beats BioNTech on 11 of the 16 factors compared between the two stocks.

How does BioNTech compare to Moderna?

BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

In the previous week, Moderna had 26 more articles in the media than BioNTech. MarketBeat recorded 46 mentions for Moderna and 20 mentions for BioNTech. BioNTech's average media sentiment score of 0.44 beat Moderna's score of 0.13 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	9 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	10 Very Positive mention(s)	10 Positive mention(s)	16 Neutral mention(s)	7 Negative mention(s)	2 Very Negative mention(s)	Neutral

BioNTech has a net margin of -63.54% compared to Moderna's net margin of -141.43%. BioNTech's return on equity of -6.86% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Moderna	-141.43%	-28.30%	-19.39%

BioNTech has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, Moderna has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BioNTech has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.42	-$1.29B	-$7.83	N/A
Moderna	$1.94B	40.35	-$2.82B	-$7.99	N/A

BioNTech currently has a consensus price target of $125.69, suggesting a potential upside of 31.96%. Moderna has a consensus price target of $78.17, suggesting a potential downside of 60.22%. Given BioNTech's stronger consensus rating and higher probable upside, analysts clearly believe BioNTech is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68
Moderna	5 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

Summary

BioNTech beats Moderna on 14 of the 17 factors compared between the two stocks.

How does BioNTech compare to argenex?

BioNTech (NASDAQ:BNTX) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

argenex has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.42	-$1.29B	-$7.83	N/A
argenex	$4.25B	13.67	$1.29B	$26.04	35.65

15.5% of BioNTech shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 2.4% of argenex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

BioNTech presently has a consensus price target of $125.69, suggesting a potential upside of 31.96%. argenex has a consensus price target of $1,158.61, suggesting a potential upside of 24.79%. Given BioNTech's higher probable upside, equities research analysts clearly believe BioNTech is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88

In the previous week, BioNTech had 16 more articles in the media than argenex. MarketBeat recorded 20 mentions for BioNTech and 4 mentions for argenex. BioNTech's average media sentiment score of 0.44 beat argenex's score of 0.43 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	9 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
argenex	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

argenex has a net margin of 32.19% compared to BioNTech's net margin of -63.54%. argenex's return on equity of 43.59% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
argenex	32.19%	43.59%	36.66%

BioNTech has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, argenex has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

Summary

argenex beats BioNTech on 12 of the 17 factors compared between the two stocks.

How does BioNTech compare to Natera?

Natera (NASDAQ:NTRA) and BioNTech (NASDAQ:BNTX) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Natera has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market.

99.9% of Natera shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 5.1% of Natera shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Natera presently has a consensus target price of $353.45, suggesting a potential downside of 10.65%. BioNTech has a consensus target price of $125.69, suggesting a potential upside of 31.96%. Given BioNTech's higher probable upside, analysts clearly believe BioNTech is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68

In the previous week, BioNTech had 2 more articles in the media than Natera. MarketBeat recorded 20 mentions for BioNTech and 18 mentions for Natera. BioNTech's average media sentiment score of 0.44 beat Natera's score of 0.26 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
BioNTech	9 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Natera has higher earnings, but lower revenue than BioNTech. Natera is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	24.72	-$208.16M	-$1.36	N/A
BioNTech	$3.25B	7.42	-$1.29B	-$7.83	N/A

Natera has a net margin of -7.11% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
BioNTech	-63.54%	-6.86%	-6.00%

Summary

Natera beats BioNTech on 9 of the 17 factors compared between the two stocks.

How does BioNTech compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and BioNTech (NASDAQ:BNTX) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Revolution Medicines has higher earnings, but lower revenue than BioNTech. Revolution Medicines is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,718.00	-$1.13B	-$8.82	N/A
BioNTech	$3.25B	7.42	-$1.29B	-$7.83	N/A

Revolution Medicines has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
BioNTech	-63.54%	-6.86%	-6.00%

Revolution Medicines presently has a consensus target price of $234.38, suggesting a potential upside of 16.68%. BioNTech has a consensus target price of $125.69, suggesting a potential upside of 31.96%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	2 Strong Buy rating(s)	2.96
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68

Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market.

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, BioNTech had 11 more articles in the media than Revolution Medicines. MarketBeat recorded 20 mentions for BioNTech and 9 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.59 beat BioNTech's score of 0.44 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	9 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Revolution Medicines beats BioNTech on 9 of the 17 factors compared between the two stocks.

Get BioNTech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNTX vs. The Competition

Export

Metric	BioNTech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$23.47B	$3.78B	$7.09B	$13.23B
Dividend Yield	N/A	3.66%	2.53%	16.47%
P/E Ratio	-11.85	13.72	275.58	25.89
Price / Sales	7.23	1,170.14	570.86	85.37
Price / Cash	71.70	118.37	77.41	52.81
Price / Book	0.96	16.04	10.77	6.26
Net Income	-$1.29B	-$22.69M	$3.50B	$382.13M
7 Day Performance	-4.19%	-4.09%	-2.35%	-1.58%
1 Month Performance	-5.95%	-13.23%	-7.81%	-5.80%
1 Year Performance	-12.69%	8.29%	2.78%	-1.78%

BioNTech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNTX BioNTech	4.0681 of 5 stars	$92.35 -3.0%	$125.69 +36.1%	-10.2%	$23.34B	$3.25B	N/A	7,807	Analyst Forecast Insider Trade
REGN Regeneron Pharmaceuticals	4.5063 of 5 stars	$752.25 -4.5%	$802.18 +6.6%	+27.2%	$81.13B	$14.34B	18.59	15,410	Analyst Forecast
MRNA Moderna	1.9376 of 5 stars	$197.28 -0.8%	$76.72 -61.1%	+618.7%	$79.40B	$1.94B	N/A	4,700	Trending News Analyst Forecast
ARGX argenex	4.6152 of 5 stars	$972.25 +1.3%	$1,158.61 +19.2%	+16.4%	$60.03B	$4.25B	37.34	1,863	Trending News Gap Down
NTRA Natera	2.1803 of 5 stars	$411.77 -0.2%	$336.07 -18.4%	+134.7%	$59.47B	$2.31B	N/A	6,140	Analyst Forecast Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNTX) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNTech (BNTX) Competitors

BNTX vs. REGN, MRNA, ARGX, NTRA, and RVMD

How does BioNTech compare to Regeneron Pharmaceuticals?

Summary

How does BioNTech compare to Moderna?

Summary

How does BioNTech compare to argenex?

Summary

How does BioNTech compare to Natera?

Summary

How does BioNTech compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX vs. The Competition

BioNTech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNTech (BNTX) Competitors

BNTX vs. REGN, MRNA, ARGX, NTRA, and RVMD

How does BioNTech compare to Regeneron Pharmaceuticals?

Do insiders & institutionals have more ownership in BNTX or REGN?

Do analysts rate BNTX or REGN?

Which has preferable earnings and valuation, BNTX or REGN?

Is BNTX or REGN more profitable?

Does the media favor BNTX or REGN?

Which has more risk & volatility, BNTX or REGN?

Summary

How does BioNTech compare to Moderna?

Does the media prefer BNTX or MRNA?

Is BNTX or MRNA more profitable?

Which has more volatility and risk, BNTX or MRNA?

Do insiders and institutionals have more ownership in BNTX or MRNA?

Which has better valuation & earnings, BNTX or MRNA?

Do analysts prefer BNTX or MRNA?

Summary

How does BioNTech compare to argenex?

Which has better valuation & earnings, BNTX or ARGX?

Do institutionals & insiders hold more shares of BNTX or ARGX?

Do analysts rate BNTX or ARGX?

Does the media prefer BNTX or ARGX?

Is BNTX or ARGX more profitable?

Which has more volatility and risk, BNTX or ARGX?

Summary

How does BioNTech compare to Natera?

Which has more risk & volatility, NTRA or BNTX?

Do institutionals and insiders hold more shares of NTRA or BNTX?

Do analysts rate NTRA or BNTX?

Does the media refer more to NTRA or BNTX?

Which has stronger valuation & earnings, NTRA or BNTX?

Is NTRA or BNTX more profitable?

Summary

How does BioNTech compare to Revolution Medicines?

Which has preferable valuation and earnings, RVMD or BNTX?

Is RVMD or BNTX more profitable?

Do analysts recommend RVMD or BNTX?

Which has more volatility and risk, RVMD or BNTX?

Do insiders & institutionals hold more shares of RVMD or BNTX?

Does the media refer more to RVMD or BNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX vs. The Competition

BioNTech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools